Soleno Therapeutics, Inc. (SLNO) Revenue Tops Expectations With $91.7M in Q4 Results, TD Cowen Maintains Buy

Soleno Therapeutics, Inc. (NASDAQ:SLNO) ranks among the most shorted stocks to buy according to analysts. On February 25, Soleno Therapeutics, Inc. (NASDAQ:SLNO) posted strong financial results for the fourth quarter of 2025, exceeding Wall Street estimates with EPS of $0.80, up from $0.61. Revenue also exceeded expectations, totaling $91.7 million compared to an expected $82.45 million, representing an 11.26% increase.

Following the earnings report, TD Cowen analyst Tyler Van Buren reduced the price target for Soleno Therapeutics, Inc. (NASDAQ:SLNO) to $85 from $120 while maintaining a Buy rating. According to the firm, Soleno experienced a solid Q4, producing $190 million in revenue from just nine months of Vykat XR sales, and ended 2025 financially viable.

Management also maintained a strong commercial trajectory for 2026, with about 1,000 new start forms expected over the next 9-12 months.

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is a clinical-stage biopharmaceutical company developing novel therapies for rare diseases, including Prader-Willi Syndrome.

While we acknowledge the potential of SLNO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None.